Superficial bladder cancer: The role of interferon-α

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 1793-1801

  Belldegrun, Arie S ^a   Franklin, John R ^a   O'Donnell, Michael A ^a   Gomella, Leonard G ^a   Klein, Eric ^a   Neri, Rudolph ^a   Nseyo, Unyime O ^a   Ratliff, Timothy L ^a   Williams, Richard D ^a  

^a NONE

Author keywords

Antineoplastic agents; Medical oncology; Urology

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BROPIRIMINE; DOXORUBICIN; ETOGLUCID; IMMUNOMODULATING AGENT; LYMPHOBLAST INTERFERON; MITOMYCIN C; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THIOTEPA;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENTIATION; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0032413238     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63160-4     Document Type: Review

References (84)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1997. CA, 47: 5, 1997.
2. Bane, B. L., Rao, J. Y. and Hemstreet, G. P.: Pathology and staging of bladder cancer. Sem. Oncol., 23: 546, 1996.
3. Catalona, W. J.: Urothelial tumors of the urinary tract. In: Campbell's Urology, 6th ed. Edited by P. C. Walsh, A. B. Retik, T. A. Stamey and E. D. Vaughan, Jr. Philadelphia: W. B. Saunders Co., chapt. 28, pp. 1094-1158, 1992.
4. Herr, H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., Jr. and Oettgen, H. F.: Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol., 13: 1404, 1995.
5. Nseyo, U. O. and Lamm, D. L.: Therapy of superficial bladder cancer. Sem. Oncol., 23: 598, 1996.
6. Lamm, D. L.: BCG in perspective: advances in the treatment of superficial bladder cancer. Eur. Urol. suppl., 27: 2, 1995.
7. Herr, H. W., Pinsky, C. M., Whitmore, W. F., Jr., Sogani, P. G., Oettgen, H. F. and Melamed, M. R.: Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology, 25: 119, 1985.
8. Herr, H. W., Pinsky, C. M., Whitmore, W. P., Jr., Sogani, P. C., Oettgen, H. F. and Melamed, M. R.: Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J. Urol., 135: 265, 1986.
9. Lamm, D. L.: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol., 134: 40, 1985.
10. Lamm, D. L.: Complications of bacillus Calmette-Guerin immunotherapy. Urol. Clin. N. Amer., 19: 565, 1992.
11. Melekos, M. D., Chionis, H., Pantazakos, A., Fokaefs, E., Paranychianakis, G. and Dauaher, H.: Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J. Urol., 149: 744, 1993.
12. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D. and Garbeglio, A.: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol., 146: 32, 1991.
13. Rübben, H., Lutzeyer, W., Fischer, N., Deutz, F., Lagrange, W., Giani, G. and members of the Registry for Urinary Tract Tumors, Rheinisch Westfälische Technische Hochschule, Aachen: Natural history and treatment of low and high risk superficial bladder tumors. J. Urol., 139: 283, 1988.
14. De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Aarden, L. A., Tetteroo, E., De Groot, E. R., Van der Meijden, A. P., Vegt, P. D., Debruyne, F. M. and Ruitenberg, E. J.: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol. Immunother., 34: 306, 1992.
15. Fujimoto, T., O'Donnell, M. A., Szilvasi, A., Yang, H. and Duda, R. B.: Bacillus Calmette-Guerin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol. Immunother., 42: 280, 1996.
16. Jackson, A. M., Prescott, S., Hawkyard, S. J., James, K. and Chisholm, G.: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol. Immunother., 36: 25, 1993.
17. Patard, J. J., Muscatelli-Groux, B., Saint, F., Popov, Z., Maille, P., Abbou, C. and Chopin, D.: Evaluation of local immune response after intravesical bacille Calmette-Guerin treatment for superficial bladder cancer. Brit. J. Urol., 78: 709, 1996.
18. Lamm, D. L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. N. Amer., 19: 573, 1992.
19. Traynelis, C. L. and Lamm, D. L.: Current status of intravesical therapy for bladder cancer. In: Urology Annual. Edited by S. N. Rous. New York: W. W. Norton and Co., vol. 8, pp. 113-143, 1994.
20. Brosman, S. A.: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J. Urol., 128: 27, 1982.
21. DeBruyne, F. M. J., van der Meijden, A. P. M., Geboers, A. D. H., Franssen, M. P. H., van Leeuwen, M. J. W., Steerenberg, P. A., de Jong, W. H. and Ruitenberg, J. J.: BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology, suppl., 31: 20, 1988.
22. Jauhiainen, K., Rintala, E., Alfthan, O. and Finnbladder Group: Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer. In: Immunotherapy of Urological Tumours. Edited by J. B. deKernion. Edinburgh: Churchill Livingstone, chapt. 2, pp. 13-26, 1990.
23. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Jr., Sullivan, J., Sarosdy, M. F., Crissman, J. and Coltman, C.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl. J. Med., 325: 1205, 1991.
24. Lamm, D. L., Crawford, E. D., Blumenstein, B., Crissman, J., deVere White, R., Wolfk, M., Lowe, B., Sarosdy, M., Schellhammer, P., Sagalowsky, A., Smith, J., Grossman, H. B., Flanigan, R., Moon, T., Brendler, C. and Coltman, C.: SWOG 8795: A randomized comparison of bacillus Calmette-Guérin and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. J. Urol., part 2, 149: 282A, abstract 275, 1993.
25. Lamm, D. L.: Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Introduction. Eur. Urol., suppl., 27: 1, 1995.
26. Martínez-Piñeiro, J. A., Jimenez León, J., Martínez-Piñeiro, L., Jr., Fiter, L., Mosteiro, J. A., Navarro, J., Garcia Matres, M. J. G. and Cárcamo, P.: Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol., 143: 502, 1990.
27. Rodrigues, N. R., Jr. and Lemos, G. C.: A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors. J. Urol., 129: 33, 1983.
28. Rübben, H., Graf-Dobbersein, C., Ostwald, R., Stauffenberg, A., Jaeger, N., Deutz, F. J., Steffens, L. and Giani, G.: Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer: mitomycin C vs BCG Connaught vs TUR alone. In: Immunotherapy of Urological Tumours. Edited by J. B. deKernion. Edinburgh: Churchill Livingstone, chapt. 3, pp. 27-36, 1990.
29. Witjes, J. A., v. d. Meijden, A. P., Witjes, W. P., Doesburg, W., Schaafsma, H. E. and Debruyne, F. M.: A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RFVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur. J. Cancer, 29A: 1672, 1993.
30. Baron, S., Tyring, S. K., Fleischmann, W. R., Jr., Coppenhaver, D. H., Niesel, D. W., Klimpel, G. R., Stanton, G. J. and Hughes, T. K.: The interferons. Mechanisms of action and clinical applications. J.A.M.A., 266: 1375, 1991.
31. Lotzova, E., Savary, C. A. and Stringfellow, D. A.: 5-halo-6-phenyl pyrimidinones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells. J. Immunol., 130: 965, 1983.
32. Lotzova, E., Savary, C. A., Khan, A. and Stringfellow, D. A.: Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidinone. J. Immunol., 132: 2566, 1984.
33. Wierenga, W.: Antiviral and other bioactivities of pyrimidinones. Pharmacol. Ther., 30: 67, 1985.
34. Tracey, D. E. and Richard, K. A.: Mechanisms of immunostimulation by pyrimidinones. In: Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance. Edited by J. A. Majde. New York: Alan R. Liss, Inc., pp. 279-289, 1987.
35. Kurzrock, R., Gutterman, J. U. and Talpaz, M.: Interferons-α, β, γ: basic principles and preclinical studies. In: Biologic Therapy of Cancer. Edited by V. T. DeVita, Jr., S. Hellman and S. A. Rosenberg. Philadelphia: J. B. Lippincott Co., chapt. 14, pp. 247-274, 1991.
36. Borden, E. C., Groveman, D. S., Nasu, T., Reznikoff, C. and Bryan, G. T.: Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J. Urol., 132: 800, 1984.
37. Fuchsberger, N., Kubes, M., Kontsek, P., Borecky, L., Hornak, M., Godal, A., Silvanova and Svec, J.: In vitro antiproliferative effect of interferon alpha in solid tumors: a potential predictive test. Neoplasma, 40: 293, 1993.
38. Giannopoulos, A., Constantinides, C., Kortsaris, A., Chrisofos, M., Pavlaki, C. and Dimopoulos, C.: Determination of interferon-α receptors in urothelial cancer and in normal urothelium. J. Urol., 157: 79, 1997.
39. Hawkyard, S., James, K., Prescott, S., Jackson, A. M., Ritchie, A. W. S., Smyth, J. F. and Chisholm, G. D.: The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J. Urol., 145: 1078, 1991.
40. Jackson, A. M., Hawkyard, S. J., Prescott, S., Ritchie, A. W. S., James, K. and Chisholm, G. D.: An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. J. Urol., 147: 207, 1992.
41. Tzai, T.-S. and Lin, S.-N.: Interferon-a can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J. Urol., 147: 523, 1992.
42. Alvarez-Mon, M., Molto, L. M., Manzano, L., Olivier, C. and Carballido, J. A.: Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anticancer Drugs, suppl., 3: 5, 1992.
43. Molto, L., Alvarez-Mon, M., Carballido, J., Manzano, L., Guillen, C., Prieto, A., Olivier, C. and Rodriguez-Zapata, M.: Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Brit. J. Cancer, 70: 1247, 1994.
44. Molto, L., Alvarez-Mon, M., Carballido, J., Olivier, C., Gimeno, F. and Manzano, L.: Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer, 75: 2720, 1995.
45. Ikemoto, S., Kishimoto, T., Wada, S., Nishio, S. and Maekawa, M.: Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes. Brit. J. Urol., 65: 333, 1990.
46. Christophersen, I. S., Jordal, R., Oster, K., Lindenberg, J., Pedersen, P. H. and Berg, K.: Interferon therapy in neoplastic disease. Acta Med. Scand., 204: 471, 1978.
47. Grups, J. W., Frohmuller, H. G. and Ackermann, R.: Can recombinant human alpha-2 interferon prevent recurrence of high-grade superficial bladder tumors? Cancer Detect. Prev., 10: 405, 1987.
48. Sargent, E. R. and Williams, R. D.: Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin. Urol. Clin. N. Amer., 19: 581, 1992.
49. Scorticatti, C. H., de de la Pena, N. C., Bellora, O. G., Mariotto, R. A., Casabe, A. R. and Comolli, R.: Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study. J. Interferon Res., 2: 339, 1982.
50. Ikic, D., Nola, P., Maricic, Z., Smudj, K., Oresic, V., Knezevic, M., Rode, B., Jusic, D. and Soos, E.: Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet, 1: 1022, 1981.
51. Di Stasi, S. M., Virgili, G., Vespasiani, G., Porena, M. and Micali, F.: Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder. A pilot study. Brit. J. Urol., 71: 422, 1993.
52. Oliver, R. T. D., Waxman, J. H., Kwok, H., Fowler, C. G., Mathewman, P. and Blandy, J. P.: Alpha lymphoblastoid interferon for non-invasive bladder cancer. Brit. J. Cancer, 53: 432, 1986.
53. Torti, F. M., Shortliffe, L. D., Williams, R. D., Pitts, W. C., Kempson, R. L., Ross, J. C., Palmer, J., Meyers, F., Ferrari, M. and Hannigan, J.: Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J. Clin. Oncol., 6: 476, 1988.
54. Glashan, R. W.: A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J. Urol., 144: 658, 1990.
55. Sarosdy, M. F., Lowe, B. A., Schellhammer, P. F., Lamm, D. L., Graham, S. D., Jr., Grossman, H. B., See, W. A., Peabody, J. O., Moon, T. D., Flanigan, R. C., Crawford, E. D. and Morganroth, J.: Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology, 48: 21, 1996.
56. Niijima, T.: Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group. Cancer Immunol. Immunother., 30: 81, 1989.
57. Geboers, A. D. H., van Bergen, T. N. L. M. and Oosterlinck, W.: Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer. J. Urol., part 2, 137: 276A, abstract 691, 1987.
58. Kostakopoulos, A., Deliveliotis, C., Mavromanolakis, E., Aravantinos, G. and Dimopoulos, M. A.: Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors. Eur. Urol., 18: 201, 1990.
59. Portillo, J., Martin, B., Hernandez, R., Correas, M., Gutierrez, J., Del Valle, J., Roca, A., Vega, A., Villanueva, A. and Gutierrez, R.: Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology, 49: 187, 1997.
60. Bartoletti, R., Massimini, G., Criscuolo, D. and Rizzo, M.: Interferon alfa 2a in superficial bladder cancer prophylaxis: toleration and long-term follow-up. A phase I-II study. Anticancer Res., 11: 2167, 1991.
61. Boccardo, F., Cannata, D., Rubagotti, A., Guarneri, D., Decensi, A., Canobbio, L., Curotto, A., Martorana, G., Pegoraro, C. and Selvaggi, F.: Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J. Clin. Oncol., 12: 7, 1994.
62. Hoeltl, W., Hasun, R., Albrecht, W. and Marberger, M.: How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer? Brit. J. Urol., 68: 495, 1991.
63. Kälble, T., Beer, M., Mendoza, E., Ikinger, U., Link, M., Reichert, H. E., Frangenheim, T., Klein, E. and Fabricius, P. G.: BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe, 33: 133, 1994.
64. Donovan, M. G., Grainger, R. and Hegarty, J. H.: A prospective, randomized study of intravesical BCG and interferon in superficial bladder cancer. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing, 1987.
65. Zerbib, M., Botto, H., Mandel, E., Colombel, P., Le Buillou, M., Rischmann, P. and Dahmani, F.: Intravesical (IV) IFN compared to BCG therapy in "high risk" superficial bladder cancer - results of a prospective multicentric randomized study. J. Urol., part 2, 157: abstract 832, 213, 1997.
66. Williams, R. D., Gleason, D. M., Smith, A. Y., Zinner, N. R., Sagalowsky, A. I., Montie, J. E., Brosman, S. A., Marks, L. S., Brito, G., Boxer, R. J., Blank, B. H., Neri, R. and Rudeen, J.: Pilot study of intravesical alfa-2b interferon for treatment of bladder carcinoma in situ following BCG failure. J. Urol., part 2, 155: 494A, abstract 735, 1996.
67. Okamoto, E., Kinne, R. K. and Sokeland, J.: Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C. J. Urol., 156: 1492, 1996.
68. Rajala, P., Kaasinen, E., Rintala, E., Jauhiainen, K., Nurmi, M., Alfthan, O. and Lahde, M.: Cytostatic effect of different strains of bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol. Res., 20: 215, 1992.
69. Pryor, K., Stricker, P., Russell, P., Golovsky, D. and Penny, R.: Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol. Immunother., 41: 309, 1995.
70. Riggs, D. R., Tarry, W. F., DeHaven, J. I., Sosnowski, J. and Lamm, D. L.: Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J. Urol., 147: 212, 1992.
71. Sarosdy, M. F. and Kierum, C. A.: Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone. J. Urol., 142: 1376, 1989.
72. Keeley, F. X., Jr., Lattime, E., McCue, P. and Gomella, L. G.: A comparison of the local immune response to intravesical alpha-interferon and bacillus Calmette-Guérin (BCG) in patients with superficial bladder cancer. J. Urol., 151: part 2, 473A, abstract 983, 1994.
73. O'Donnell, M. A., Chen, X., Luo, Y. and DeWolf, W. C.: Experimental and clinical evidence of enhancement of BCG efficacy by adding interferon-alpha. J. Urol., part 2, 157: 383, abstract 1502, 1997.
74. O'Donnell, M. A. and DeWolf, W. C.: Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg. Oncol. Clin. N. Amer., 4: 189, 1995.
75. Lattime, E. C., Gomella, L. G. and McCue, P. A.: Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res., 52: 4286, 1992.
76. Engelmann, U., Knopf, H. J. and Graff, J.: Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer - a prospective, controlled three-armed trial. Project Group Bochum - interferon and superficial bladder cancer. Anticancer Drugs, suppl., 3: 33, 1992.
77. Ferrari, P., Castagnetti, G., Pollastri, C. A., Ferrari, G., Tavoni, F. and Grassi, D.: Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin. Anticancer Drugs, suppl., 3: 25, 1992.
78. Pavone-Macaluso, M., Tripi, M., Ingargiola, G. B., Corselli, G., Pavone, C. and Serretta, V.: Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin. J. Chemother., 5: 207, 1993.
79. Serretta, V., Piazza, S., Pavone, C., Piazza, B. and Pavone-Macaluso, M.: Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder. Urology, 47: 647, 1996.
80. Stricker, P., Pryor, K., Nicholson, T., Goldstein, D., Golovsky, D., Ferguson, R., Nash, P., Ehsman, S., Rumma, J., Mammen, G. and Penny, R.: Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology, 48: 957, 1996.
81. Bercovich, E., Deriu, M., Manferrari, F. and Irianni, G.: BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch. Ital. Urol. Androl., 67: 257, 1995.
82. Downs, T., Szilvasi, A. and O'Donnell, M. A.: Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alfa 2b. J. Urol., 158: 2311, 1997.
83. Keating, M. J., McLaughlin, P., Plunkett, W., Robertson, L. E., O'Brien, S., Gandhi, V., Gregoire, V., Yang, L. and Cabanillas, F.: Fludarabine - present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann. Oncol. suppl., 5: 79, 1994.
84. Sarosdy, M. F., Lamm, D. L., Williams, R. D., Moon, T. D., Flanigan, R. C., Crawford, E. D., Wilks, N. E., Earhart, R. H. and Merritt, J. A.: Phase 1 trial of oral bropirimine in superficial bladder cancer. J. Urol., 147: 31, 1992.